AI Article Synopsis
- * There are 14 known types of MODY, which typically follows an autosomal dominant inheritance pattern, often seen across multiple generations in families.
- * Recent studies challenge the idea that diabetic ketoacidosis (DKA) excludes a diagnosis of MODY, highlighting new cases where MODY patients have presented with DKA, forming the basis of this review.
Article Abstract
Maturity-onset diabetes of the young (MODY) is the most frequent monogenetic diabetes form. It is caused by mutations in genes important for the development and function of pancreatic beta-cells, resulting in impaired insulin secretion capacity. Up to now, 14 different types have been described. The inheritance pattern is autosomal dominant, leading to a strong family history with more than three affected generations. Young age at diagnosis and lack of pancreatic autoantibodies are further characteristics of MODY. The presence of diabetic ketoacidosis (DKA) was long regarded as an exclusion criterion for MODY. However, in recent years, several case reports on MODY patients presenting with DKA have been published. The present study aimed to give an overview of the current knowledge of DKA in MODY patients, with a collection of published case studies as a prerequisite for this review.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2338-8136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes.
Endocrinol Diabetes Metab Case Rep
January 2025
Summary: Palmoplantar keratoderma (PPK), characterised by excessive epidermal thickening of the skin on the palms and/or plantar surfaces of the feet, can be hereditary or acquired. Here, we report a case of a 53-year-old woman with a history of sub-optimally controlled diabetes mellitus presenting with fevers and decreased Glasgow Coma Scale (GCS) to a tertiary hospital. She was diagnosed with diabetic ketoacidosis (DKA), with blood glucose at 40 mmol/L and ketones at 7 mmol/L, in the setting of a methicillin-sensitive Staphylococcus aureus necrotising soft tissue back infection.
View Article and Find Full Text PDFSerum Phosphorus and Hypophosphatemia During Therapy of Diabetic Ketoacidosis in Children: Single-Center, Retrospective Cohort 2016-2022.
Pediatr Crit Care Med
January 2025
Division of Medical Critical Care, Department of Pediatrics, Boston Children's Hospital, Boston, MA.
Objectives: To assess factors associated with serum phosphorus (P) and hypophosphatemia in children with type 1 diabetes mellitus (T1DM) treated for diabetic ketoacidosis (DKA).
Design: Retrospective cohort.
Setting: Community-based PICU in a university-affiliated hospital.
A Case of Euglycemic Diabetic Ketoacidosis in a Patient with Diabetic Foot Syndrome.
Int J Low Extrem Wounds
January 2025
Diabetic Foot Section, Pisa University Hospital, Pisa, Italy.
Euglycemic Diabetic ketoacidosis (E-DKA) is a life-threatening emergency characterized by ketonemia and metabolic acidosis in presence of relatively normal glycemic values. In recent years it has been associated with some predisposing conditions including sodium-glucose transporter 2 inhibitors (SGLT2-i) therapy, widely used in high-risk cardiovascular patients. We report the case of a 78-year-old diabetic woman treated with dapagliflozin, affected by critical limb threatening ischemia and septic osteoarthritis of interphalangeal joint of first right toe.
View Article and Find Full Text PDFA Case of Euglycemic Diabetic Ketoacidosis Associated With a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Cureus
December 2024
Family Medicine, Louisiana State University Health Sciences Center, Alexandria, USA.
Euglycemic diabetic ketoacidosis is a rare metabolic derangement seen in both type 1 and type 2 diabetes. Initially characterized decades ago, the prevalence of euglycemic diabetic ketoacidosis has increased in recent years following the introduction of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Here, we present a case of euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors.
View Article and Find Full Text PDFManagement, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.
Nat Rev Endocrinol
January 2025
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Immune-related adverse events (irAEs), including endocrine irAEs, can occur in response to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Of the endocrine irAEs, pituitary and thyroid irAEs are most frequently observed, followed by primary adrenal insufficiency, type 1 diabetes mellitus and hypoparathyroidism. Notably, pituitary irAEs and type 1 diabetes mellitus can be lethal if overlooked, potentially leading to adrenal crisis and diabetic ketoacidosis, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!